People · Operator
Named in public records as an officer, director or promoter · active 2018–2026 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals Holding Co LLC | — | Pharmaceuticals | Series D+ | $130.0M | $3.9B | 2021 |
| Caldera Therapeutics, Inc. | — | Biotechnology | Series B | $37.5M | $139.2M | 2026 |
| Akriveia Therapeutics, LLC | — | Biotechnology | Series A | $7.5M | $108.5M | 2018 |
Michael Gladstone at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Gladstone on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Beck | 1 | 7 |
| Aaron Royston | 1 | 7 |
| Derek DiRocco | 1 | 7 |
| David Grayzel | 1 | 6 |
| Daniel Becker | 1 | 5 |
| John Josey | 1 | 3 |
| Michelle Doig | 1 | 3 |
| Simon Tomlinson | 1 | 2 |
| JULIE PAPANEK GRANT | 1 | 2 |
| Praveen Tipirneni | 1 | 2 |
| Natalie Holles | 1 | 2 |
| Benjamin Auspitz | 1 | 2 |
| Xiaodi Su | 1 | 1 |
| Jeremy Bender | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.